Exclusive Summary

• - Patent barriers have expired globally; adenosine injection is fully genericized and suitable for rapid multi-country entry via distribution.
• - An estimated 2.4–3.2 million new PSVT episodes occur worldwide annually, plus steady demand from myocardial perfusion imaging, driving hospital and EMS stocking.
• - Listed on the WHO Model List and recommended by AHA/ESC as first-line for regular narrow-QRS PSVT, with a very short half-life (<10 seconds) for safety and control.
• - Full SKU set (6 mg/2 mL, 60 mg/20 mL, 90 mg/30 mL) matches ED bolus and pharmacologic stress infusion (~0.84 mg/kg), improving tender win rate and departmental coverage.
• - Compared with originators and alternatives (e.g., regadenoson), generics offer ~70–90% cost savings, with simplified registration (solution BE waivers) and stable supply.